Artelo Biosciences, Inc. (ARTL) Stock

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing treatments that target the modulation of the endocannabinoid system. Founded in 2011 and headquartered in Solana Beach, California, the company focuses on developing and commercializing innovative therapies to address significant medical needs.

At the forefront of Artelo Biosciences' product candidate pipeline is ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical trials for the treatment of cancer-related anorexia. The company also pioneers ART12.11, a synthetic cannabidiol cocrystal intended for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD). Additionally, ART26.12, a fatty acid binding protein 5 inhibitor, holds promise for treating prostate and breast cancer, as well as PTSD.

Artelo Biosciences collaborates closely with leading institutions such as Trinity College Dublin to expand the therapeutic applications of its products. Formerly known as Reactive Medical, Inc., the company rebranded as Artelo Biosciences, Inc. in April 2017 to better reflect its strategic focus on harnessing the potential of the endocannabinoid system in treating diverse medical conditions. With a robust research and development agenda, Artelo Biosciences continues to drive innovation in biopharmaceuticals from its California headquarters.